These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 7902685)

  • 1. [Dopexamine: a new dopaminergic agonist].
    Perrin G; Papazian L; Martin C
    Ann Fr Anesth Reanim; 1993; 12(3):308-20. PubMed ID: 7902685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopexamine hydrochloride. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in acute cardiac insufficiency.
    Fitton A; Benfield P
    Drugs; 1990 Feb; 39(2):308-30. PubMed ID: 1970288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of acute haemodynamic effects of dopexamine hydrochloride, dobutamine and sodium nitroprusside in chronic heart failure.
    Baumann G; Gutting M; Pfafferott C; Ningel K; Klein G
    Eur Heart J; 1988 May; 9(5):503-12. PubMed ID: 3402466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inotropic, vascular and neuroendocrine effects of dopexamine hydrochloride and comparison with dobutamine.
    Jaski BE; Peters C
    Am J Cardiol; 1988 Aug; 62(5):63C-67C. PubMed ID: 3407597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the haemodynamic effects of dopexamine and dobutamine in patients with severe congestive heart failure.
    Tan LB; Littler WA; Murray RG
    Int J Cardiol; 1991 Feb; 30(2):203-8. PubMed ID: 2010243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopexamine in congestive heart failure: how do the pharmacological activities translate into the clinical situation?
    Meinertz T; Drexler H; Just H
    Basic Res Cardiol; 1989; 84 Suppl 1():177-86. PubMed ID: 2573340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An introduction to the pharmacologic properties of Dopacard (dopexamine hydrochloride).
    Smith GW; O'Connor SE
    Am J Cardiol; 1988 Aug; 62(5):9C-17C. PubMed ID: 2900602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cardiovascular actions of dopexamine hydrochloride, an agonist at dopamine receptors and beta 2-adrenoceptors in the dog.
    Smith GW; Hall JC; Farmer JB; Simpson WT
    J Pharm Pharmacol; 1987 Aug; 39(8):636-41. PubMed ID: 2888855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arrhythmogenic potential of dopexamine hydrochloride during halothane anaesthesia in dogs.
    Neustein SM; Dimich I; Sampson I; Sadeghi A; Mezrow C; Shiang H
    Can J Anaesth; 1994 Jun; 41(6):542-6. PubMed ID: 7915210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative significance of dopamine receptors, beta adrenoceptors and norepinephrine uptake inhibition in the cardiovascular actions of dopexamine hydrochloride.
    Goldberg LI; Bass AS
    Am J Cardiol; 1988 Aug; 62(5):37C-40C. PubMed ID: 2841837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beneficial haemodynamic effects of intravenous dopexamine in patients with low-output heart failure.
    Tan LB; Littler WA; Murray RG
    J Cardiovasc Pharmacol; 1987 Sep; 10(3):280-6. PubMed ID: 2444775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [New dopamine agonists in cardiovascular therapy].
    Girbes AR; Van Veldhuisen DJ; Smit AJ
    Presse Med; 1992 Aug 29-Sep 5; 21(27):1287-91. PubMed ID: 1359528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemodynamic and renal effects of dopexamine and dobutamine in patients with reduced cardiac output following coronary artery bypass grafting.
    MacGregor DA; Butterworth JF; Zaloga CP; Prielipp RC; James R; Royster RL
    Chest; 1994 Sep; 106(3):835-41. PubMed ID: 7915979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the effects of dopexamine, a novel DA1 receptor and beta 2-adrenoceptor agonist, on cardiac function and splanchnic circulation in a canine model of hemorrhagic shock.
    Chintala MS; Moore RJ; Lokhandwala MF; Jandhyala BS
    Naunyn Schmiedebergs Arch Pharmacol; 1993 Mar; 347(3):296-300. PubMed ID: 8097568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in regional blood flow distribution induced by infusions of dopexamine hydrochloride or dobutamine in anesthetized dogs.
    Biro GP; Douglas JR; Keon WJ; Taichman GC
    Am J Cardiol; 1988 Aug; 62(5):30C-36C. PubMed ID: 3407595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged infusion of varied doses of dopexamine hydrochloride for low cardiac output after cardiac surgery.
    Santman FW
    J Cardiothorac Vasc Anesth; 1992 Oct; 6(5):568-72. PubMed ID: 1358247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Organ blood flow and distribution of cardiac output in dopexamine- or dobutamine-treated endotoxemic rats.
    van Lambalgen AA; van Kraats AA; Mulder MF; van den Bos GC; Teerlink T; Thijs LG
    J Crit Care; 1993 Jun; 8(2):117-27. PubMed ID: 8102078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular pharmacology of dopexamine in low output congestive heart failure.
    Leier CV; Binkley PF; Carpenter J; Randolph PH; Unverferth DV
    Am J Cardiol; 1988 Jul; 62(1):94-9. PubMed ID: 2898209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Central and renal hemodynamic effects of a new agonist at peripheral dopamine- and beta-2 adrenoreceptors (dopexamine) in patients with heart failure.
    Jamison M; Widerhorn J; Weber L; Campese V; Vasquez J; Hovanessian L; Rahimtoola SH; Elkayam U
    Am Heart J; 1989 Mar; 117(3):607-14. PubMed ID: 2537556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of a short-term (6-h) intravenous infusion of dopexamine in patients with severe congestive heart failure: a randomized, double-blind, parallel, placebo-controlled multicenter study.
    Gollub SB; Elkayam U; Young JB; Miller LW; Haffey KA
    J Am Coll Cardiol; 1991 Aug; 18(2):383-90. PubMed ID: 1677368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.